Live Breaking News & Updates on Nasdaq Xfor|Page 3

Stay updated with breaking news from Nasdaq xfor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Adam S. Mostafa Sells 5,417 Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Stock

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR – Get Rating) CFO Adam S. Mostafa sold 5,417 shares of the firm’s stock in a transaction dated Thursday, June 15th. The shares were sold at an average price of $2.22, for a total transaction of $12,025.74. Following the transaction, the chief financial officer now directly owns 88,279 shares in the […] ....

Adams Mostafa , Stifel Nicolaus , Pharmaceuticals Daily , Management Company , Parkman Healthcare Partners , Pharmaceuticals Company Profile , Pharmaceuticals Stock Down , Cantor Fitzgerald , Pharmaceuticals Inc , Get Rating , Stock Down , Healthcare Partners , Asset Management , X4 Pharmaceuticals , Nasdaq Xfor , Insider Trading , Nsider Trades ,

Paula Ragan Sells 6,292 Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Stock

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR – Get Rating) CEO Paula Ragan sold 6,292 shares of the company’s stock in a transaction dated Wednesday, May 31st. The stock was sold at an average price of $1.95, for a total value of $12,269.40. Following the completion of the transaction, the chief executive officer now directly owns 557,245 shares […] ....

Stifel Nicolaus , Paula Ragan , Virtu Financial , Wealth Group , Pharmaceuticals Daily , Pharmaceuticals Stock Performance , Connor Clark Lunn Investment Management Ltd , Pharmaceuticals Inc , Securities Exchange Commission , Cantor Fitzgerald , Get Rating , Exchange Commission , Lunn Investment Management , Jane Street Group , X4 Pharmaceuticals , Nasdaq Xfor , Insider Trading , Nsider Trades ,

Paula Ragan Sells 6,292 Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Stock

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR – Get Rating) CEO Paula Ragan sold 6,292 shares of the firm’s stock in a transaction on Wednesday, May 31st. The stock was sold at an average price of $1.95, for a total transaction of $12,269.40. Following the completion of the transaction, the chief executive officer now directly owns 557,245 shares […] ....

Stifel Nicolaus , Paula Ragan , York Mellon Corp , Securities Exchange Commission , Virtu Financial , Pharmaceuticals Company Profile , Connor Clark Lunn Investment Management Ltd , Cantor Fitzgerald , Renaissance Technologies , Pharmaceuticals Inc , Pharmaceuticals Daily , Pharmaceuticals Stock Performance , Get Rating , Exchange Commission , New York Mellon Corp , Street Group , Connor Clark , Lunn Investment Management , X4 Pharmaceuticals , Nasdaq Xfor , Insider Trading , Nsider Trades ,

X4 Pharmaceuticals (NASDAQ:XFOR) Price Target Increased to $5.00 by Analysts at Stifel Nicolaus

X4 Pharmaceuticals (NASDAQ:XFOR – Get Rating) had its price objective raised by Stifel Nicolaus from $4.00 to $5.00 in a research report sent to investors on Wednesday morning, The Fly reports. XFOR has been the topic of a number of other reports. B. Riley lowered their price objective on shares of X4 Pharmaceuticals from $7.00 […] ....

Stifel Nicolaus , Pharmaceuticals Inc , Jpmorgan Chase Co , Perceptive Advisors , Pharmaceuticals Trading Down , Pharmaceuticals Daily , Pharmaceuticals Company Profile , Geode Capital Management , Schonfeld Strategic Advisors , Cantor Fitzgerald , Get Rating , Trading Down , Capital Management , Strategic Advisors , X4 Pharmaceuticals , Nasdaq Xfor , Boost Price Target ,

Analysts Set Expectations for X4 Pharmaceuticals, Inc.'s FY2027 Earnings (NASDAQ:XFOR)

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR – Get Rating) – Investment analysts at HC Wainwright boosted their FY2027 EPS estimates for shares of X4 Pharmaceuticals in a research note issued to investors on Friday, May 5th. HC Wainwright analyst S. Ramakanth now expects that the company will earn $0.29 per share for the year, up from their […] ....

Adams Mostafa , Pharmaceuticals Trading Down , Pharmaceuticals Daily , Cantor Fitzgerald , Management Company , Pharmaceuticals Inc , Bain Capital Life Sciences Investors , Vanguard Group Inc , Get Rating , Trading Down , Capital Life Sciences Investors , X4 Pharmaceuticals , Nasdaq Xfor , Earnings Estimates , Hc Wainwright ,